Introduction {#sec0001}
============

The latest 21^st^-century pandemic, coronavirus disease 2019 (COVID-19) by the etiological agent, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), has led to a worldwide disruption of human activities. Globally, as of 21^st^ August 2020, SARS-CoV-2 had infected **22,536,278 people** including **789,197 deaths,** a**s** reported by the WHO [@bib0001]. The unprecedented clinical challenges posed by human-to-human transmission of SARS-CoV-2, begin with a range of clinical manifestations including fever, cough, and dyspnoea with no or mild pneumonia. Severe cases presented dyspnoea, hypoxia, and \>50% pulmonary damage requiring intensive care for respiratory support, while the critical cases were characterized by respiratory and multi-organ failure. SARS-CoV is also known to cause the common complication of acute respiratory distress syndrome (ARDS) in patients, thus requiring mechanical ventilation [@bib0002].

The high morbidity and mortality rates worldwide demonstrate that there seem to be differential responses in COVID-19 patients. The global imperative of the current hour is to rapidly develop immune therapy to prevent COVID-19 [@bib0003] . Hence, it is necessary to understand the immunological basis of this infection, the implications of which will offer a better insight into the development of new therapies. [Extracorporeal membrane oxygenation (ECMO), is one of the evolving strategies which can be utilized in treating patients with refractory hypoxemia and altered lung properties despite optimal conventional treatment including mechanical ventilation \[]{.ul} [@bib0004] [\]. Combining antiviral and anti-inflammatory treatments is being investigated. Efforts to repurpose drugsfor COVID-19 with the challenge of appropriate dosage remains an attractive treatment modality \[]{.ul} [@bib0005] [\]. Many studies have also tried to investigate the function of glucocorticoids to modulate inflammation mediated lung injury, thereby mitigating the progression of respiratory failure and mortality \[]{.ul} [@bib0006] [\].]{.ul}

SARS-CoV-2: the escape pathogen {#sec0002}
===============================

The first event in the chronology of SARS-CoV-2 infection is virus binding to a host cell. The cytopathic virus utilizes its spike glycoprotein (S) located on its surface to bind with the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. Various research groups have targeted the receptor-binding domain (RBD) of SARS-CoV, SARS-CoV-2, and MERS-CoV with neutralizing antibodies to combat the infection [\[]{.ul} [@bib0007] [\]]{.ul}. S protein has two functional subunits- S1 subunit mediates cell attachment and S2 subunit involved in the fusion of viral and cellular membrane [\[]{.ul} [@bib0008] [\]]{.ul}. SARS-CoV-2 principally targets airway, alveolar and vascular epithelial cells, and lung macrophages, all of which express the ACE2 entry receptor. SARS-CoV-2 in complex with ACE2 is endocytosed by cells. As a result of the inaccessibility of ACE2 to regulate the renin-angiotensin system (RAS), blood pressure and electrolyte imbalance occur [\[]{.ul} [@bib0009] [\]]{.ul}. Furthermore, loss of ACE2 also promotes accumulation of Ang II (Angiotensin II) which eventually activates ADAM-17 (A disintegrin and metalloproteinase 17) activity, perpetuating membrane shedding of ACE2, RAS overactivation and inflammation [\[]{.ul} [@bib0010] [,]{.ul} [@bib0011] [\]]{.ul}. Zhu et al.. investigated the morphogenetic process and cytopathic effect of SARS-CoV-2 infection in the organotropic human airway epithelial cultures [\[]{.ul} [@bib0012] [\]]{.ul}. It was observed that the virus infected both ciliated and secretory cells due to which, the authors suggest the possibility of more receptors in addition to ACE2. This is because ACE2 is mainly expressed on ciliated epithelial cells of the human lungs [\[]{.ul} [@bib0012] [\]]{.ul}. Viral infection and replication in the upper respiratory tract epithelial cells induce pyroptosis. This inflammatory phenomenon of programmed cell death is commonly observed in SARS-CoV infected cells too [\[]{.ul} [@bib0013] [\]]{.ul}. The epidemiology working group for NCIP Epidemic Response, reported the differential fatality rate in males and females where the percentage of death was more in males than in females [\[]{.ul} [@bib0014] [\]]{.ul}. This correlates with the immunoregulatory functions of estrogen and testosterone [\[]{.ul} [@bib0015] [\]]{.ul}. A cellular serine protease TMPRSS2 is observed to process the S protein and eventually contribute to the host cell entry. Hence, TMPRSS2 is also a potential drug target that has attracted a lot of attention in the field of repurposed drugs against SARS-CoV-2 [\[]{.ul} [@bib0014] [\]]{.ul}.

The immunity battles {#sec0003}
====================

The destruction of pulmonary cells initiates a local immune response involving macrophages and monocytes which release an array of cytokines. This action also primes the adaptive immunity by T and B cells. The mild cases of COVID-19 are primarily resolved at this stage. However, severe lung destruction is associated with a dysfunctional immune response. Pyroptosis of the airway epithelial cells releases IL-1β, a potential trigger for the eventual inflammatory response [\[]{.ul} [@bib0016] [\]]{.ul}. This wave of local inflammation is sensed by the alveolar epithelial cells and alveolar macrophages ensuing the secretion of pro-inflammatory cytokines and chemokines like IL-6, IFN-γ, MCP1, and IP-10. This starts the pulmonary recruitment of monocytes and T lymphocytes into the infected site. Thus, the infiltration of lymphocytes into the respiratory airway manifests into T cell lymphopenia, observed in majority of COVID-19 patients [\[]{.ul} [@bib0013] [,]{.ul} [@bib0017] [\]]{.ul}.

The escape pathogen SARS-CoV-2 can sabotage the innate response by antagonism of the interferon response like SARS-CoV and disrupt the host protein translation process. This could potentially support viral replication and eventually manifest into pyroptosis associated-aberrant inflammation in the lungs [\[]{.ul} [@bib0013] [,]{.ul} [@bib0018] [\]]{.ul}.

In most of the mild cases, the recruited immune cells clear the respiratory airway after which the immune response recedes. But a dysfunctional immune response is observed in severe cases which triggers a massive cytokine storm that mediates extensive lung inflammation. The cytokine storm involves elevated blood plasma levels of macrophage inflammatory protein 1α (MIP1α) and tumor necrosis factor (TNF), IL-2, IL-7, IL-10, IP-10, MCP1, and granulocyte monocyte colony-stimulating factor (GM-CSF). Also, a high population of CD14^+^CD16^+^ inflammatory monocytes, which also contribute to the cytokine storm, is also observed in severe cases. Lymphocyte counts in the peripheral blood are also observed to remarkably decrease [\[]{.ul} [@bib0019] [\]]{.ul}. Other observed consequences of T cell lymphopenia and cytokine storm are hyaluronan formation and pulmonary edema. This contributes to severe breathlessness and vulnerability to secondary infections. The ripple effect of the cytokine storm brings about myocardial damage and multi-organ failure [@bib0003]. Transcriptomic analysis of three COVID-19 patients revealed a dynamic early immune response. After reaching a lowest point in the respiratory function, a peak in most of the inflammatory and cytokine signalling gene expression, except expression in IL-1 pathway which preceded the decrease in respiratory function, was observed [@bib0020].

B cell immune response is concomitantly observed 1 week after the onset of symptoms. The antibody response is observed against nucleocapsid and S protein by week 3 of SARS-CoV infection symptoms. However, it is seen that some COVID-19 patients do not develop long-lasting antibodies \[[@bib0013], [@bib0021]\]. While a lot of studies represent significant inroads, a clear understanding of the important host immune factors involved in the development of COVID-19 inflammation remains incompletely defined.

COVID-19 and comorbidities {#sec0004}
==========================

The most distinctive comorbidities of fatalities or severe cases of COVID-19 have been diabetes, cerebrovascular diseases, hypertension, coronary heart diseases, and cancer. Since cells expressing ACE2 are normally found in the epithelial lining of lungs, intestine, kidney, and blood vessels, it only makes patients with comorbidities susceptible to SARS-CoV-2 [@bib0022]. Most therapies routinely prescribed for these comorbidities, favour the gateway of SARS-CoV-2 ([Table 1](#tbl0001){ref-type="table"} ). While the efforts to develop targeted immune therapies and vaccines are underway, many health organizations are advocating the practice of yoga, Ayurveda, and maintaining a healthy lifestyle to boost immunity \[[@bib0023],[@bib0024]\].Table 1Current therapies recommended for COVID-19 comorbiditiesTable 1Sl. noComorbidityCurrent therapyRisksReference1.Diabetes (type I and II)in patients treated with ACE inhibitors and angiotensin II type I receptor blockers (ARBs)Increased expression of ACE2, poor prognosis[@bib0025]2Hypertension, Cardiovascular diseasesACE inhibitors, ARBs, ibuprofen, thiazolidinedionesIncreased expression of ACE2, poor prognosis\[[@bib0026],[@bib0027]\]3Inflammatory lung diseasesantibiotics of macrolides or quinolone, and steroidsOvershooting inflammation[@bib0026]4Cancersurgery or chemotherapyThe risk for significant severity due to delays in treatment and low immunity.\[[@bib0028],[@bib0029],[@bib0030]\]5Liver injuryantibiotics of macrolides or quinolone, and steroidsOvershooting inflammatory response[@bib0031]6Autoimmune diseases: rheumatoid arthritisCorticosteroids, NSAIDs, and acetaminophen, TNF-inhibitors,Increased risk of secondary infection due to immunosuppression\[[@bib0032],[@bib0033]\]

Non-vaccine pharmacological swords against SARS-CoV-2 {#sec0005}
=====================================================

While some labs are involved in repurposing old antiviral drugs against the novel virus, some are involved in designing a definite immune therapy. Remedesivir and lopinavir have presented potential antiviral effect and are being clinically investigated for safety and efficacy [@bib0034]. The efficacy of corticosteroid treatment for lung inflammation is also being questioned due to complications and delayed clearance of the infection [@bib0033]. Clinical trials to validate the efficacy of the anti-malarial drug, hydroxychloroquine which is also used to treat certain autoimmune diseases (lupus and rheumatoid arthritis), anti-cytokine therapies like IL-6 inhibitors, and mesenchymal stromal cell-based therapies in COVID-19 patients are underway [@bib0035]. In such a scenario, where the production of an effective vaccine and antiviral medicines are underway, convalescent plasma therapy and nanobodies have become exciting non-vaccine pharmacological tools for prevention [@bib0036].

Convalescent plasma (CP) therapy- a pandemic saviour? {#sec0006}
=====================================================

This is a typical adaptive immunotherapy applied successfully to stem outbreaks of SARS, MERS, H1N1 pandemic of 2009, poliomyelitis, measles, and mumps \[[@bib0037],[@bib0038],[@bib0039]\]. However, the application of CP could not treat the Ebola virus disease. Since SARS, MERS, and COVID-19 share some similarities in the immunopathogenesis of their etiological agent, CP is looked upon as a promising option in treating COVID-19 \[[@bib0039],[@bib0040]\]. It has been reported by Walls et al.., that murine SARS-CoV S protein polyclonal antibodies could inhibit S protein mediated SARS-CoV-2 entry, shedding light on cross-neutralizing antibodies that target the S epitope [@bib0041].

A study by Duan et al.., on the feasibility of CP therapy transfusion in COVID-19 patients, reported that a cohort of severe adult patients tolerated the therapy and it significantly uplifted the titer of neutralizing antibodies, leading to the reduction of clinical symptoms within 3 days and disappearance of viremia in a week [@bib0042]. In a trial by China National Biotec Group Co (<http://www.chictr.org.cn/showprojen.aspx?proj=49861>), it has been reported that 10 severe COVID-19 patients receiving CP therapy demonstrated significant improvement in oxygenation and pulmonary injury. Mechanistically, the high-titer specific neutralizing antibodies could bring about complement activation and phagocytosis [@bib0042].

The key factors associated with CP therapy are neutralizing antibody titer, treatment time point, and safety. Earlier studies on CP therapy for MERS-CoV demonstrated that the antibody titer should exceed 1:80 for full clearance. Hence, it is a prerequisite to find donors who have high titers. It has been observed in SARS-CoV and MERS-CoV infected individuals that IgG titer reaches undetectable levels after 3-4 months of recovery. Hence, it can be concluded that neutralizing antibodies represented transient humoral immune response, and plasma from newly recovered patients should be more effective. The neutralizing antibody titer of recently recovered COVID-19 patients was above 1:640, which is higher than that of MERS patients [@bib0042].

SARS patients who were given CP before 14 days post-onset of illness (dpoi) demonstrated a better outcome. Similarly, in Duan and co-workers' study, the patients who received CP transfusion before 14 dpoi exhibited a spike in lymphocyte count and reduction in C-reactive protein, which is a marker of inflammation and cytokine storm. Patients who received CP after 14 dpoi showed relatively less improvement, emphasizing the importance of an optimal transfusion time point [@bib0042]. The Stony Brook Hospital, New York has initiated trials to test CP therapy for COVID-19 patients (<https://clinicaltrials.gov/ct2/show/NCT04344535>). Recently, the US Food and Drug Administration (FDA) approved the access to CP for COVID-19 patients while emphasising on regulatory measures and clinical trials, before routinely administering this therapy [@bib0043]. It was reported that worldwide use of this therapy has mushroomed very rapidly due to encouraging results in patients [@bib0044]. In a study by Joyner et al., early implications of CP therapy in 500 severe or life-threatening COVID-19 individuals of diverse races in the median age of 62 years were studied [@bib0043]. They observed \<1% severe adverse events including 0.3% mortality within first four hours of transfusion. The seven-day mortality rate was 14.9% which could also be due to underlying multi-organ failure, sepsis and other significant comorbidities. The authors discussed the possibility of developing transfusion related acute lung injury (TRALI) and transfusion associated circulatory overload (TACO) as the associated pulmonary complications post therapy which are often difficult to identify. TACO results in circulatory overload followed by pulmonary oedema and hypertension. TRALI is characterized by bilateral pulmonary edema with or without acute respiratory distress syndrome (ARDS) risk factors. In certain cases, it was observed that an underlying lung injury or comorbidities in COVID-19 patients further complicate the diagnosis of TACO and TRALI which could exacerbate transfusion related risks in severe patients [@bib0043]. Transmission of pathogen is also a major risk associated with CP therapy [@bib0040]. To maintain the activity of the antibodies and inactivate the virus in the donated plasma, Duan et al.., applied methylene blue photochemistry, which is reported to be better than UV-C light [@bib0042]. Earlier studies on CP therapy for Ebola have reported transfusion-related acute lung injury. Antibody-dependent infection enhancement can be an uncommon risk which could suppress innate antiviral immunity and thus tolerate intracellular growth of the virus. However, it can be assumed that due to the high titer of neutralizing antibodies, optimal time of infusion and transfusion volume, the risk of antibody-dependent infection can be avoided. Thus, the use of CP therapy can be beneficial for COVID-19 patients [@bib0045].

Hyperimmune globulin treatment- A safe option? {#sec0007}
==============================================

Nguyen et al.. define hyperimmune globulin as a product that is manufactured from convalescent plasma from thousands of donors with high antibody titers to a specific pathogen. It consists of an immune globulin fraction with well-defined properties [@bib0046]. Plasmapheresis derived plasma from recovered COVID-19 patients, has been proposed to obtain polyclonal hyperimmune globulin. This approach has already been explored for patients with SARS and severe influenza. It has been routinely used to treat hepatitis B and rabies virus infected patients proving its precedence and sound therapeutic plausibility. Díez et al.., tested the hypothesised cross-reactivity using currently available intravenous immunoglobulin (IVIg) products, Gamunex-C and Flebogamma DIF with SARS-CoV-2, SARS-CoV and MERS-CoV [@bib0047]. The authors observed noteworthy cross-reactivity to antigenic components including the S protein. It has been anticipated that in acutely ill COVID-19 patients, vaccine administration may not be able to elicit an immune response of high magnitude. The hyperimmune globulin treatment could treat viral infection and reduce the cytokine storm in severely ill COVID-19 patients. To date, a number of mechanisms for anti-inflammatory effects of IVIg therapy have been discussed including anti-complement mechanisms, anti-idiotypic neutralization of pathogenic auto-antibodies, regulation via Fc receptors, enhanced production of regulatory T cells and inhibition of Th17 differentiation [@bib0047]. Hence, there have been suggestions for intravenous immunoglobulin therapy [@bib0048]. Although this needs to be confirmed through clinical trials. Takeda company is advocating with regulatory agencies in US, Asia and Europe to expediate the use of **Anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG)** to treat high risk patients of COVID-19 [@bib0049]. This could be a life-saving medicine for thousands of patients nearing SARS-CoV-2 fatality.

Therapeutic monoclonal antibodies against SARS-CoV-2: current scenario and challenges {#sec0008}
=====================================================================================

Many companies and academic laboratories across the world are striving to develop therapeutic antibodies against SARS-CoV-2 for the emergency prophylaxis and treatment of COVID-19. Regeneron, AstraZeneca, GlaxoSmithKline, AbCellera, Eli Lilly and Company, Vir Biotechnology, Inc., ImmunoPrecise, Mount Sinai Health System, and Harbour BioMed (HBM) are some of the companies actively involved in developing the functional therapeutic antibodies against SARS-COV-2 [@bib0050]. Regeneron\'s double mAbs combination, REGN-COV-2 and LY-CoV555, a therapeutic antibody developed by Eli Lilly in collaboration with Abcellera are in Phase 3 and Phase 2 clinical trials, respectively \[<https://clinicaltrials.gov/ct2/show/NCT04452318;https://clinicaltrials.gov/ct2/show/NCT04427501>\].Memory B cells of convalescent COVID-19 patient is the most used source for the identification of high affinity neutralizing antibodies against SARS-CoV-2 \[[Figure 1](#fig0001){ref-type="fig"} \]. Another potential source is human trails testing for vaccines since an early immune response to the antigen is enough to release specific neutralizing antibodies with a high binding affinity [@bib0051]. S-RBD is an effective candidate as a bait to screen the antibody-producing memory B cells for developing therapeutics and diagnostics for SARS-CoV-2.Figure 1SARS-CoV-2 neutralizing mAbs production using single B cell repertoire from recovered COVID-19 patient [@bib0053]. Created with BioRender.comFigure 1

The SARS-CoV-2 has a genome sequence that is 79.6% identical to that of SARS-CoV and 96% identical to the bat coronavirus [@bib0052] The RBD sequences of SARS-COV-2 share 73.8--74.9% amino acid identity with that of SARS-CoV [@bib0053]. Both SARS-CoV and SARS-CoV-2 possess a conserved epitope in RBD, which makes it cross-reactive [@bib0054]. S glycoprotein of SARS-CoV-2 has ten times higher affinity to ACE2 than that of SARS-CoV; much of this affinity is attributed to RBD\'s structural features such as a more compacted ACE2-binding ridge and well-stabilized hotspots \[[@bib0055],[@bib0056]\]. CR3022, a neutralizing antibody obtained from a convalescent SARS-CoV infected patient had cross-reacted with SARS-CoV-2 S, but could not cross-neutralize SARS-CoV-2 *in vitro* [@bib0054]. A Cross-reactive mAb that neutralizes both SARS-CoV and SARS-CoV-2 pseudoviruses and authentic viruses has been generated using transgenic H2L2 mice immunized with a combination of S~ecto~ from different coronaviruses such as HCoV-OC43, SARS-CoV and MERS-CoV **\[** [Figure 2](#fig0002){ref-type="fig"} **\]**, though identified mAb exhibited higher binding affinity towards SARS-CoV S [@bib0008].Figure 2SARS-CoV-2 neutralizing mAbs production using transgenic H2L2 mice [@bib0008]. Created with BioRender.comFigure 2

Past research on the development of therapeutic antibodies for SARS-CoV serves as a backbone for the development of the feasible therapeutic antibodies for SARS-CoV-2. In 2004, Sui et al.. (2004) reported high-affinity humanized mAbs (hmAbs) based on single-chain variable region fragments (scFvs) 80R against S1 domain of S protein of the SARS-CoV [@bib0057]. These could effectively neutralize SARS-CoV and blocked the S1-protein binding with ACE2. However, the 80R was not effective against the GD03 strain of SARS CoV, which caused the second outbreak in 2003/2004. Zhu et al.., reported that hmAbs, m396 and S230 which successfully cross-reacted with the GD03 strain, the Urbani and Tor2 isolates (first SARS outbreak) and SZ3 and SZ16 (pseudotyped viruses bearing spikes from palm civet), except bat derived strains. Both antibodies block the SARS-CoV--ACE2 interaction by binding to the RBD of SARS-CoV Se protein [@bib0058]. When 80R, m396 and S230 were tested against SARS-CoV-2 RBD, none of them showed significant binding regardless of the high degree of structural homology between SARS-CoV S RBD and SARS-CoV-2 S RBD. Hence, SARS-CoV-2 S protein would be the ideal probe for the design of therapeutic mAbs against SARS-CoV-2 [@bib0055].Yi et al.., gave some interesting insight into the critical amino acid differences in SARS-CoV and SARS-CoV-2 RBDs, which result in their distinct immunogenicity and limit the cross-neutralizing activity of therapeutic antibodies [@bib0059].

[Table 2](#tbl0002){ref-type="table"} summarizes the neutralizing mAbs with therapeutic potential against SARS-CoV-2 reported so far. Cao et al.., identified some potent SARS-CoV-2 mAbs based on the CDR3H structural similarity to SARS-CoV-neutralizing mAbs \[m396 and 80R\] from the large antigen-binding clonotype library produced by high throughput single-cell 5′ mRNA and VDJ sequencing [@bib0062]. mAbs derived from memory B cells of a SARS-survivor were cross-reactive to SARS-CoV and SARS-CoV-2, but not to OC43 and MERS-CoV [@bib0061]. Similarly, Sarbecovirus cross-neutralizing antibodies were identified from memory B cells of a SARS-survivor [@bib0064]. However, SARS-CoV-2 generated mAbs showed no cross-reactivity to SARS-CoV and MERS-CoV RBDs [@bib0063]. Mechanism of action of SARS-CoV-2 neutralizing mAbs is either by blocking the interaction between RBD and hACE2 or by binding to the conserved epitope of spike RBD without competing for receptor binding. Neutralizing human mAbs exhibiting intense competition with hACE receptor for RBD binding are quite potent against SARS-CoV-2 \[[@bib0062],[@bib0063]\]. Yi et al. reported that RBD-binding affinity and neutralizing ability of SARS-CoV-2 targeted mAbs generated by phage display was much weaker for SARS-CoV which strengthens the species-specific nature of anti-RBD antibodies \[[@bib0059],[@bib0063]\]. A cocktail of mAbs binding to the different epitopes on RBD will be more efficacious in neutralizing of SARS-CoV-2 and preventing immune escape mutants rather than monotherapy with a candidate therapeutic mAb \[[@bib0053],[@bib0062]\].Table 2Neutralizing antibodies with therapeutic potential against SARS-CoV-2 (Abbreviations: NI-not investigated)Table 2:mAbsSourceMechanisms of neutralizationIC50*In vivo* studyReferences47D11Transgenic H2L2 miceBinds to the conserved epitope of spike RBD0.061 μg/ml (SARS-CoV-2 pseudotyped virus)\
0.57 μg/ml (SARS-CoV-2 virus)NA[@bib0008]311mAb-31B5\
311mAB-32D4RBD-specific single B cell repertoire from recovered COVID-19 patientBlocking the binding of SARS-CoV-2 RBD to hACE2311mAb-31B5=0.0338 μg/ml\
311mAb-32D4=0.0698 μg/ml (SARS-CoV-2 pseudotyped virus)NI[@bib0060]B38\
H4RBD-specific single B cell repertoire from COVID-19 patientBlocking the binding of SARS-CoV-2 RBD to hACE2B38 =0.177 μg/ml\
H4=0.896 μg/ml\
(SARS-CoV-2 virus)hACE2 transgenic mice model[@bib0053]HA001Phage displayBlocking the binding of SARS-CoV-2 RBD to hACE20.016 μg/ml (SARS-CoV-2 pseudotyped virus)NI[@bib0059]S309Memory B cells of person previously infected with SARS-CoVBinds to the conserved epitope of spike RBD79 ng/ml (SARS-CoV-2 virus)NI[@bib0061]BD-368-2High throughput scRNA/VDJ-sequencing of COVID-19 convalescent patient' B cellBlocking the binding of SARS-CoV-2 RBD to hACE21.2 ng/ml (SARS-CoV-2 pseudotyped virus)\
15 ng/ml (SARS-CoV-2 virus)hACE2 transgenic mice model[@bib0062]PC2-1F11\
P2B-2F6\
P2C-1A3RBD-specific single B cell repertoire from COVID-19 patientBlocking the binding of SARS-CoV-2 RBD to hACE2PC2-1F11=0.03 μg/ml\
P2B-2F6=0.05 μg/ml\
P2C-1A3=0.62 μg/ml\
(SARS-CoV-2 pseudotyped virus)\
PC2-1F11=0.03 μg/ml\
P2B-2F6=0.41 μg/ml\
P2C-1A3=0.28 μg/ml\
(SARS-CoV-2 virus)NI[@bib0063]ADI-56046RBD-specific single B cell repertoire from SARS-CoV survivorBind to the conserved epitopes in the RBD and compete with hACE2 binding≈0.05 μg/ml\
(SARS-CoV-2 pseudotyped virus)\
\<0.1 μg/ml\
(SARS-CoV-2 virus)NI[@bib0064]COV2-2196, COV2-2130,\
COV2-2381SARS-CoV-2 S2P~ecto~ or RBD--mFc-reactive single B cells from convalescent COVID-19 patientsBlocking the binding of SARS-CoV-2 RBD to hACE2COV2-2196 = 0.7 ng/ml\
COV2-2130 = 1.6 ng/ml\
(SARS-CoV-2 pseudotyped virus)\
COV2-2196 = 15 ng/ml\
COV2-2130 = 107 ng/ml\
(SARS-CoV-2 virus)Ad-hACE2 mouse model and rhesus macaque model[@bib0065]CC12.1SARS-CoV-2 RBD and S antigen specific single memory B cell from convalescent COVID-19 patientsTarget RBD-A epitope by competing with hACE2 and block its binding to SARS-CoV-2 RBD0.019 μg/ml (SARS-CoV-2 pseudotyped virus)\
0.022 μg/ml (SARS-CoV-2 virus)Syrian hamster model[@bib0066]REGN10933\
REGN10987Anti SARS-CoV-2 antibodies from immunized VI mouse and RBD specific single B cells from convalescent COVID-19 patientsBlocking the binding of SARS-CoV-2 RBD to hACE2REGN10933-42 pM\
REGN10987- 40 pM\
(SARS-CoV-2 pseudotyped virus)\
REGN10933-37 pM\
REGN10987- 42 pM\
(SARS-CoV-2 pseudotyped virus)Rhesus macaque model and golden hamster model[@bib0067]CB6RBD specific memory B cells from convalescing COVID-19 patientsBlocking the binding of SARS-CoV-2 RBD to hACE2ND~50~- 0.036 μg/ml (SARS-CoV-2 pseudotyped virus)\
ND~50~- 0.036 μg/ml (SARS-CoV-2 virus)Rhesus macaque model[@bib0068]4A8SARS-CoV-2 S specific single B cells from convalescent COVID-19 patientsViral neutralization by targeting NTD of S1.EC~50~- 49 μg/ml (SARS-CoV-2 pseudotyped virus)\
EC~50~- 0.61 μg/ml (SARS-CoV-2 virus)NI[@bib0069]H014SARS-CoV-2 RBD binding antibody from Phage displayBlocking the binding of SARS-CoV-2 RBD to hACE23 nM ((SARS-CoV-2 pseudotyped virus)\
38 nM (SARS-CoV-2 virus)hACE2 transgenic mice model[@bib0070]COVA1-18,\
COVA2-15SARS-CoV-2 S specific single B cells from convalescent COVID-19 patientsCompetitively blocking hACE2 binding to RBDCOVA1-18- 0.008 μg/ml\
COVA2-15- 0.008 μg/ml (SARS-CoV-2 pseudotyped virus)\
COVA1-18- 0.007 μg/ml\
COVA2-15- 0.009 μg/ml (SARS-CoV-2 virus)NI[@bib0071]2-15SARS-CoV-2 S specific single memory B cells from COVID-19 patientsTarget RBD of SARS-CoV-2 and block its binding to hACE20.005 μg/ml (SARS-CoV-2 pseudotyped virus)\
0.0007 μg/ml (SARS-CoV-2 virus)Golden Syrian hamster model[@bib0072]414-1SARS-CoV-2 S1 or RBD specific single memory B cells from convalescent COVID-19 patientsBinds to the epitope-A at RBD3.09 nM (SARS-CoV-2 pseudotyped virus)\
1.75 nM (SARS-CoV-2 virus)NI[@bib0073]CV30SARS-CoV-2 S specific single B cells from COVID-19 patientsTarget RBD of SARS-CoV-2 and block its binding to hACE20.03 μg/ml (SARS-CoV-2 pseudotyped virus)NI[@bib0074]

A major concern that should be addressed before implementation of antibody-based drug therapy or vaccine is Antibody-dependent enhancement (ADE) of viral infection, in which the virus-specific antibodies facilitate viral entry to immune cells by cross-linking the viral-antibody or virus activated complement complex to cell-surface Fc receptor or complement receptor, leading to viral replication, subsequently high viral load \[[@bib0075],[@bib0076]\]. ADE has been reported for other coronaviruses \[[@bib0077],[@bib0078],[@bib0079]\]. Antibody-dependent infection of SARS-CoV-1 could allow the virus to widen the tropism by providing additional entry routes and contribute to the pathogenicity. In ADE of SARS-CoV-1 infection, anti-Spike antibodies mediate viral entry to the immune cells by cross-linking the virus-antibody complexes to the Fcγ receptor II followed by internalization through a pH- and cysteine protease-independent pathway, which is distinct from hACE2 mediated endosomal/lysosomal pathway [@bib0078]. Wan et al.., demonstrated cell surface IgG Fc receptor-mediated viral entry of MERS-CoV into Fc-receptor expressing cells through canonical viral-receptor-dependent pathways [@bib0079]. It has been suggested that low concentration of neutralizing antibodies could cause ADE of SARS-CoV-2, as reported in the case of SARS-CoV-1 \[[@bib0080], [@bib0081], [@bib0082]\]. Specificity, concentration, affinity and isotope of the antibody are the factors that influence the infection enhancing tendency of antibody. Designer antibodies with higher affinity to RBD are less likely to induce ADE [@bib0081]. Engineering the Fc region of mAbs to abolish its affinity for Fcγ receptor is a feasible solution to mitigate the risk of ADE [@bib0080]. To abrogate the risk of ADE of SARS-CoV-2, LALA mutations were introduced to the Fc region of CB6, a potent SARS-CoV-2 neutralizing antibody. CB6 (LALA) effectively reduced viral load and infection-related lung damage associated with SARS-CoV-2 infection in rhesus macaques [@bib0068]. Possibility of ADE can also be minimized by maintaining a high concentration of circulating therapeutic antibodies, which is easier to be achieved by improving the half-life of mAbs [@bib0083]. Lurie et al.., suggested that rigorous animal testing and preclinical trials should be conducted for the therapeutic candidates against SARS-CoV-2, considering the adverse effects caused by ADE [@bib0084]. The current uncertainty about the duration of functional protection by antibodies to SARS-CoV-2 RBD till the second wave of infection must be addressed to enhance the therapeutic efficacy of the monoclonal antibody products [@bib0085].

The ability of a virus to generate escape mutants due to immune pressure is a major challenge for a successful vaccine and a therapeutic antibody development. A pandemic scenario influenced by a highly diverse infected population also facilitates the generation of escape mutants [@bib0086]. RNA virus such as SARS-CoV-2 exhibits a high mutation rate, up to a million times higher than its host, which drives viral evolution and adaptability \[[@bib0087],[@bib0088]\]. High viral load of SARS-CoV-2 at the early stage of the disease might also contribute to antiviral resistance [@bib0089]. Molecular modelling simulation studies of antigen-antibody complex predict the mutation of antigen that could disrupt the binding of Ab and reduce the efficacy of mAb therapy [@bib0090]. It has been reported that escape mutants attenuate SARS-CoV infection Formulation of more than one therapeutic antibody that binds to non-overlapping epitopes and/or parts of S other than RBD has been proposed to neutralize the resistant variants \[[@bib0091],[@bib0092]\]. A cocktail of mAbs S227.14 and S230.15 had effectively cross-reacted with a broad range of human and zoonotic SARS-CoV isolates including escape mutants [@bib0093]. The mAbs combination targeting NTD as well as RBD of SARS-CoV-2 could be effective against viral escape [@bib0069]. Single antibody treatment against SARS-CoV-2 induced escape mutants. Regeneron\'s mAbs cocktail, REGN10933 and REGN10987, each binds to the distinct epitopes of RBD prevented generation of escape mutants [@bib0094].

An effective passive immune therapy along with stimulation of the endogenous humoral and cellular immune response can provide durable protective immunity. Combining mAbs with immunostimulatory agents or altering antibody effector function through Fc-engineered mAbs, are the possible options to improve the long-lasting protective vaccine-like effects of mAbs [@bib0095]. Half-life and effector functions of S309, a mAb with neutralizing activity against SARS-CoV-2 were improved by FC engineering [@bib0061].

The prospect of highly potent super-antibodies that can neutralize multiple viruses of a single-family look quite promising in terms of developing a broadly- active therapeutic agents against the Coronaviridae viruses. Large scale screening for a donor with broadly neutralizing serum and a high throughput B cell isolation are the critical steps involved in the discovery of super-antibodies [@bib0096]. Defining the immunodominant regions of the S protein of SARS-CoV-2 is critical as it can reveal potential targets for immune response. Development of mAbs targeting conserved epitopes of RBD and highly similar S2 subdomain is likely to give cross-protection across betacoronaviruses \[[@bib0071], [@bib0097]\].

Immunomodulation of cytokine storm syndrome using mAbs therapy: a need of the hour {#sec0009}
==================================================================================

Targeted drug development is a time-consuming process. Repurposed drugs and therapeutic mAbs that modulate the immune response and improve the prognosis of COVID-19 patients should be considered at this critical time until a successful drug is out on the market for viral clearance. An anti-IL6 mAb, Tocilizumab, routinely used in the treatment of rheumatoid arthritis has been found to mitigate the cytokine storm syndrome and improve the outcome of COVID-19 patients. Apart from the anti-inflammatory action of Tocilizumab, its role in halting the coagulation activation greatly benefits the COVID-19 patients with severe coagulopathy, which make this therapy a very effective treatment than the general anti-inflammatory interventions [@bib0098]. Tocilizumab has been recommended for critical COVID-19 patients with significantly high levels of IL-6 in China and India \[[@bib0099],[@bib0100]\]. It has also been suggested that mAbs targeting GM-CSF might also give a promising result for the intervention of inflammatory cytokine storm caused by SARS-CoV-2 and a clinical trial is underway (<https://clinicaltrials.gov/ct2/show/NCT04341116>). Since TNF also is a major player in the inflammatory responses, targeting it with an anti-TNF antibody is also a feasible strategy to reduce the COVID-19 induced lung inflammation and related inflammatory markers [@bib0101]. Administration of anti-C5a mAbs is also presumed to have a role in the mitigation of COVID-19 associated lung injury [@bib0050].

Nanobodies as a promising therapeutic agent against SARS-COV-2 {#sec0010}
==============================================================

Llama based nanobodies have been implicated in designing antiviral therapy against HIV, rotavirus and respiratory syncytial virus \[[@bib0102], [@bib0103], [@bib0104]\]. Nanobodies are fully functional single domain antibodies obtained from the Camelid family, comprising of a single variable domain (VHH) instead of two variable domains as in the case of the human antibody. Their small size (≈14 kDa), good solubility and excellent stability along with high antigen specificity make them a superior candidate over the conventional antibodies [@bib0105]. Nanobodies can be easily produced in yeast or bacterial host by recombinant technology [@bib0106]. The potency of nanobodies can be enhanced by engineering monovalent VHH into multivalent VHH [@bib0102].

SARS-CoV S-directed VHH (SARS VHH-72) generated in immunized llama, cross-reacted with SARS-CoV-2 S-protein. Though the binding of SARS VHH-72 to the SARS-CoV-2 RBD-SD1 was weaker, an engineered bivalent VHH Fc construct resulted in successful neutralization of SARS-CoV-2 pseudoviruses *in vitro*. Upon binding of VHH, RBD undergoes a dynamic conformational change that prevents its binding to the host cell receptor. Antibody panning with SARS-CoV-2 S can yield VHH with more stable binding and affinity toward SARS-CoV-2 RBD [@bib0107]. Further investigation is warranted to determine the feasibility of nanobodies as antiviral therapy. Two nanobodies H11-D4 and H11-H4 that neutralize SARS-CoV-2 by blocking the RBD and hACE2 interaction were identified by Huo et al.. [@bib0108]. Fully human single-domain antibodies against SARS-CoV-2 were constructed using the human single domain antibody phage-displayed library [@bib0109]. An engineered trivalent nanobody with remarkable potency and stability was made into an inhalable formulation that could give protection against SARS-CoV-2, though effectiveness is yet to be proven by clinical trials [@bib0110].

Cellular Immune therapy for SARS-CoV-2 infection: a field worth to explore? {#sec0011}
===========================================================================

T cells play an important role in the viral clearance of SARS-CoV. The reduction in viral titre and improvement of survival was observed in SARS-CoV infected SCID or BALB/c mice on adoptive transfer of in vitro generated SARS-CoV-specific effector CD4+ and CD8+ T cells [@bib0111]. Channappanavar et al.., suggested that boosting virus-specific memory T cell responses of the host can be a good therapeutic strategy against SARS-CoV infection [@bib0112]. A drastic reduction of total T cells was reported in COVID-19 patients [@bib0113]. Sekine et al.., demonstrated T cell phenotypes associated with acute and convalescent COVID-19 patients [@bib0114]. Strong memory T cell responses were elicited in mild and asymptomatic COVID-19 patients implicating the potential role of T cells in immunity against SARS-CoV-2 [@bib0114]. A clinical trial is ongoing for the treatment of severe COVID-19 patients using clinical-grade SARS-CoV-2 specific T cells from the blood of convalescent donors (<https://www.clinicaltrials.gov/ct2/show/NCT04351659>). However, serious concerns such as donor matching and induction of cytokine storm should be addressed before the implication of adoptively transferred Tcells for viral infection [@bib0115].

Conclusions {#sec0012}
===========

Unlike a newly emerged virion, the distance to a successful immunotherapy against SARS-CoV-2 is not long, as there were some advances in the therapeutic management of infections caused by previously emerged coronaviruses - SARS-CoV and MERS-CoV. CP therapy and a more refined approach, IVIg are the currently available effective treatment options for SARS-CoV-2 infection. Human mAbs that prevent the viral entry into the host by inhibiting viral attachment to the receptor show efficient SARS-CoV-2 neutralization in vitro and in vivo. The protective ability of a developed therapeutic antibody can be challenged by viral mutation under selection pressure. Combination of mAbs has been a promising approach to overcome the emergence of escape mutants. Treatment benefits of these promising candidates can only be known by randomized-controlled trials. Further, if therapeutic candidates are proven safe and efficacious in the treatment of SARS-CoV-2 infection, the policymakers should be well-equipped for the mass-production and distribution of antiviral therapeutics in response to the pandemic threat. Apart from the lack of a successful therapy, the high mortality rate of COVID-19 has been attributed to the paucity of understanding about immunopathology of SARS-CoV-2 infection and underlying comorbidities. Triggering immunomodulation using mAbs targeting inflammatory cytokines can be used to treat the life-threatening cytokine storm syndrome. Though developing therapeutic antibodies targeting SARS-CoV-2 is the primary need of the current scenario, designing super-antibodies that neutralize multiple coronaviruses can make the world ready to tackle a future outbreak caused by coronaviruses.
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